List view / Grid view
Although pre-targeting is still in its infancy, it has immense potential to increase state-of-the-art radioligand therapies. In this Q&A, PreTT reveals how their pre-targeted RLTs surpass traditional methods, transforming cancer treatment.
The new findings could lead to new therapeutics and a method to diagnose pancreatic cancer earlier, improving its prognosis.
The discovery that genomic deletions cause altBRAFs can help develop new therapies to overcome drug resistance in BRAF-mutant melanoma.
Mutation signatures and recurrent copy number alterations correlated with a higher risk for disease progression.
Researchers mapped the bacteria present in over 4000 metastatic tumour biopsies, which could enable the exploration of new treatments.
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
In this Q&A, Curve Therapeutic’s Chief Scientific Officer Professor Ali Tavassoli discusses how dual HIF inhibition could combat solid tumours.
Dr Richard Cote and Dr Ramaswamy Govindan of the Washington University School of Medicine elucidate how AI, particularly deep learning networks, could identify histopathologic features in non-small cell lung cancer, and impact the treatment approach for early-stage patients.
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.
In this episode, we explore the current status and potential solutions to addressing major hurdles in oncology.
New understanding of the CRC and its interaction with STAT3 could lead to novel therapeutics and combination strategies.
Pharmacological concomitant therapies or further genetic improvement of CAR T-cells can increase their effectiveness against TP53-mutant AML cells.
New findings will enable the development of safer PARP inhibitors that inhibit PARP’s enzymatic activity without trapping it on DNA.
Researchers have discovered two distinct lineages of Fusobacterium nucleatum, which has great implications for colorectal cancer screening and therapeutics.
